TobaccoReporter logo

Tag: altria

  • Altria Reports Q1 2026 Results; Reaffirms Full-Year Guidance

    Altria Reports Q1 2026 Results; Reaffirms Full-Year Guidance

    Altria Group reported a strong start to 2026, delivering solid financial growth and reaffirming full-year earnings guidance. First-quarter net revenues rose 3.2% to $5.4 billion, while adjusted diluted earnings per share (EPS) increased 7.3% to $1.32, driven by higher operating income and reduced share count. The company continues to generate significant cash flow, enabling shareholder returns through $1.8 billion in dividends and $280 million in share repurchases during the quarter. Management maintained its full-year adjusted EPS outlook of $5.56 to $5.72, reflecting confidence in continued performance despite macroeconomic uncertainty.

    Operationally, Altria’s smokeable products segment remained the primary earnings driver, supported by pricing strength and Marlboro’s continued leadership in the premium category. While overall cigarette shipment volumes declined due to industry contraction, income growth and margin expansion offset these pressures. In the oral tobacco segment, the on! nicotine pouch brand showed volume growth and ongoing national expansion, though competitive dynamics and shifting product mix weighed on margins. The company continues to balance investment in emerging smoke-free products with maintaining profitability in its core combustible business.

    Strategically, Altria said it is advancing its “Moving Beyond Smoking” vision by investing in smoke-free alternatives and long-term growth initiatives. The company is navigating moderated e-vapor category growth, regulatory constraints, and evolving consumer preferences, while also investing in manufacturing capabilities and cost-efficiency programs. Although near-term challenges include declining cigarette volumes and competitive pressure in oral products, Altria said its strong cash generation, disciplined capital allocation, and diversified nicotine portfolio position it to sustain earnings growth and shareholder value over the long term.

  • Altria Outperforms Peers as Cigarette Declines Moderate: Motley Fool

    Altria Outperforms Peers as Cigarette Declines Moderate: Motley Fool

    A recent Motley Fool analysis highlights continued declines in U.S. cigarette volumes, though at a slower pace than expected, with industry data showing a 4.3% to 5.5% year-over-year drop and a 5.1% decline so far in 2026. The figures came in better than earlier projections, suggesting the rate of contraction in the traditional cigarette market may be stabilizing somewhat, even as long-term declines persist.

    The report notes that Altria is outperforming key competitors in this environment, with its cigarette volumes down 4.7% compared to sharper declines of 9.3% for British American Tobacco and 9% for Imperial Brands. At the same time, Motley Fool said next-generation products show mixed performance, with nicotine pouches growing 22% while e-cigarette volumes fell 17%, underscoring uneven momentum across reduced-risk categories as companies continue to navigate the transition away from combustible products.

  • Altria Expands Investment in U.S. Tobacco Communities

    Altria Expands Investment in U.S. Tobacco Communities

    Altria Group announced that it is launching a series of new investments aimed at supporting U.S. tobacco growers, agricultural research, and rural communities, as part of a broader initiative tied to America’s 250th anniversary. The company, with funding support from Philip Morris USA, said it plans to commit more than $8 million over the next three years toward agricultural education, community development, and industry sustainability efforts.

    A significant portion of the funding will establish endowments at the University of Kentucky and Virginia Tech, each receiving $2 million to support faculty positions and research focused on tobacco agronomy and innovation. The initiative is designed to strengthen long-term agricultural capacity, support growers facing evolving market conditions, and advance research into tobacco production and alternative uses. Additional funding will be directed toward donor-advised community funds in key tobacco-growing regions, aimed at addressing local needs and providing disaster relief support.

    The program also includes expanded employee engagement efforts, with nearly 6,000 employees expected to participate in volunteerism, charitable giving, and civic initiatives. Altria said the broader goal is to reinforce its longstanding relationships with U.S. tobacco farmers while supporting the sustainability and resilience of tobacco-growing communities as the industry continues to evolve.

  • Massachusetts Court Upholds $56M Verdict Against Philip Morris

    Massachusetts Court Upholds $56M Verdict Against Philip Morris

    Massachusetts’ highest court rejected an effort by Philip Morris USA to impose stricter standards on punitive damages, allowing a previously reduced $56 million verdict to stand. The company had sought additional legal limits to curb large punitive awards, but the court declined to adopt new rules.

    The case stems from a lawsuit in which the original $1 billion punitive damages award had already been significantly reduced by a lower court. Philip Morris argued for further reductions and broader changes to how such damages are assessed, but the justices upheld the existing framework.

  • Altria to Host Q1 Webcast April 30

    Altria to Host Q1 Webcast April 30

    Altria Group, Inc. announced it will host a live audio webcast on April 30 at 9 a.m. EST to discuss its 2026 first-quarter business results, and plans to issue a press release containing its business results two hours earlier. The webcast can be accessed at altria.com.

    During the webcast, Billy Gifford, Altria’s Chief Executive Officer, and Sal Mancuso, Altria’s Chief Financial Officer, will discuss the Company’s 2026 first-quarter business results and answer questions from the investment community and news media.

    The webcast will be in a listen-only mode. Pre-event registration is necessary; directions are posted at www.altria.com/webcasts. An archived copy of the webcast will be available on altria.com.

  • Altria Raises Cigarette Prices Across Most Brands

    Altria Raises Cigarette Prices Across Most Brands

    Altria increased prices across its portfolio earlier this week, including a roughly 20- to 25-cent per pack hike on Marlboro, 25 cents on Benson & Hedges, Merit, Parliament, and Virginia Slims, and a 20-cent increase on L&M cigarettes, according to a notice from Goldman Sachs. The company held pricing flat on its value-focused Basic brand. The price changes were the second increase this year, according to CSP.

    Goldman Sachs Managing Director Bonnie Herzog said the increases were unsurprising and followed Altria’s “typical quarterly cadence,” but that the increases were sharper than predicted. “We believe Altria’s sophisticated and targeted pricing strategies, as well as promotional spending, should help to offset the frequency of list price increases, especially for price-sensitive consumers,” Herzog said.

    Herzog also said she expected British American Tobacco to follow soon with a similar price increase on cigarettes, and that she would be watching to see whether deep-discount cigarette manufacturers also move on price. “If they don’t, the relative price gap could widen further,” Herzog was quoted by CSP, increasing the risk of downtrading, but Herzog said brands like Marlboro, with a loyal customer base, would likely be able to keep consumers within the franchise.

  • KT&G Preparing Pilot Line for Oral Nicotine Product

    KT&G Preparing Pilot Line for Oral Nicotine Product

    KT&G is developing a smokeless nicotine product designed for oral absorption and is preparing a pilot production line for research and development in South Korea, according to local media outlet The Elec. The pilot equipment will be supplied by PNT, a manufacturer known for roll-to-roll battery and display production systems. KT&G said the project is in an early stage and that plans for domestic or international commercialization of nicotine pouches or related products have not been finalized.

    The move aligns with growing global competition in nicotine pouches, led by brands such as Zyn and VELO. KT&G last year participated with Altria in the acquisition of Scandinavian pouch companies ASF AB and ASF AS. In South Korea, however, nicotine pouches currently lack formal sales authorization under the Tobacco Business Act, and products are primarily obtained through overseas purchases or unofficial channels, meaning any domestic launch would be dependent on regulatory changes.

  • RJR Seeks to Block Lawyer’s Live Testimony in Altria Dispute

    RJR Seeks to Block Lawyer’s Live Testimony in Altria Dispute

    R.J. Reynolds Vapor Co. asked a North Carolina court to quash a trial subpoena that would require one of its in-house attorneys to testify in person at an evidentiary hearing in an ongoing royalty dispute with Altria Group. The company argues that a previously recorded deposition of the attorney should suffice, saying live testimony would be unnecessary and burdensome.

    The dispute centers on royalty obligations tied to vaping technology and agreements between the rival firms. Reynolds maintains that compelling its lawyer to appear would intrude on privileged matters and exceed what is needed for the court to assess the evidentiary issues. The matter is before a judge in North Carolina, who will decide whether the deposition recording can replace in-court testimony.

    Source: Law 360 (pay)

  • FDA’s Pouch Fast-Track Scheme Stalling Over Youth Worries

    FDA’s Pouch Fast-Track Scheme Stalling Over Youth Worries

    A fast-track review program at the U.S. Food and Drug Administration aimed at accelerating authorizations for nicotine pouch products has stalled, as agency scientists weigh concerns about youth uptake and risks to non-users against potential harm-reduction benefits for smokers, according to sources cited by Reuters. Reuters said applications tied to pouch brands from Philip Morris International (Zyn) and British American Tobacco (Velo) remain under review despite expectations that decisions would be made by the end of 2025 under the pilot scheme. The FDA has already authorized six products under Altria Group’s on! brand, but reviewers are said to be taking a more cautious stance on other applications where evidence of net public-health benefit is viewed as less clear-cut.

    While FDA data shows pouch use among middle- and high-school students remains relatively low, it has been rising, prompting heightened scrutiny. Tobacco companies argue the pilot program is critical for restoring legal market competition amid a surge of unregulated products, while public-health advocates warn that rapid authorizations could fuel new addiction trends. The FDA said decisions continue to be guided by science and statutory standards rather than external pressure.

  • FDA Releases Raw NYTS Data Without Comment

    FDA Releases Raw NYTS Data Without Comment

    Last week, the U.S. Food and Drug Administration released the raw data from the 2025 National Youth Tobacco Survey (NYTS), an annual, school-based survey that collects data on tobacco use among students in grades 6 through 12 across the country. Unlike previous years, the FDA released the data without comment, leaving industry members to interpret it independently.

    The survey tracks students’ tobacco behaviors, attitudes, and exposure to pro- and anti-tobacco messaging, providing nationally representative data. First conducted in 1999, it has guided youth tobacco policy and was jointly run by the U.S. Food and Drug Administration and Centers for Disease Control and Prevention since 2012, before moving fully under FDA oversight in 2025. 

    “Youth use of tobacco and nicotine has been the FDA’s sole focus in its policy and decision making for so many years, with adult education programs centered on the risk continuum of these products seemingly still far off,” said Laura Leigh Oyler, VP of Regulatory Affairs at Nicokick.com. “It’s been a big question throughout the industry as to why they’ve chosen to release this data with no fanfare, and with no guidance on how to interpret it. The FDA has essentially left the industry and other stakeholders to analyze and determine the use rates on their own.”

    Altria Client Services released a “high-level” summary of the data, finding overall tobacco usage by middle and high school students declined for the third straight year, dropping to 7.5%, the lowest rate since the study became annual in 2011, and down from the all-time high of 23.3% in 2019.

    Cigarette usage remained steady at 1.4%, while all other categories dropped from 2024, with e-cigarettes going from 5.9% to 5.2%, pouches from 1.8% to 1.7%, smokeless tobacco going from 1.2% to 0.6%, and heated tobacco products going from 0.8% to 0.7%.

    “With the continued low youth use rates, we think this is something worth celebrating,” Oyler said. “The data shows that targeted public‑health interventions, combined with thoughtful regulation like raising the legal age for nicotine purchases, can make a meaningful difference.”

    “The law is clear: tobacco and nicotine products are strictly for adults 21 and older,” said Matthew T. Sheaff, director of U.S. regulatory communications for Philip Morris International. “At PMI U.S., we are committed to guarding against underage access to our products, while continuing to provide adults 21 and older with better alternatives to smoking and traditional tobacco.

    “For example, we direct our marketing to adult nicotine consumers and do not pay social media influencers to endorse our products in the U.S. This is a shared responsibility—regulators, policymakers, retailers, and manufacturers all have an important role to play.”

    With the news generally positive in terms of youth usage, Oyler suggested emphasis be given to adults 55 and older, whose smoking rates have remained mostly steady, dropping from 18.7% in 2016 to 16.7% in 2023.

    “If anything, this data raises questions less about youth access and more about what we can do to educate adults on the differences between nicotine and tobacco products, and how they can reduce their risk,” Oyler said. “This is the population most at risk of smoking-related disease. This is the population with the most to gain from moving away from cigarettes. And this is the population that has been historically underserved by cessation efforts and innovation.

    “To drive the next major improvement in public health, we must accelerate support for adults who smoke and ensure that they have access to better alternatives, and ultimately, better outcomes.”